Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PMVP 
Pmv Pharmaceuticals Inc (PMVP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: PMVP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.4
1 Year Target Price $8.4
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.92% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.90M USD | Price to earnings Ratio - | 1Y Target Price 8.4 |
Price to earnings Ratio - | 1Y Target Price 8.4 | ||
Volume (30-day avg) 5 | Beta 1.51 | 52 Weeks Range 0.81 - 1.84 | Updated Date 10/29/2025 |
52 Weeks Range 0.81 - 1.84 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.11% | Return on Equity (TTM) -45.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -68126608 | Price to Sales(TTM) - |
Enterprise Value -68126608 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.24 | Shares Outstanding 52990864 | Shares Floating 36704652 |
Shares Outstanding 52990864 | Shares Floating 36704652 | ||
Percent Insiders 2.9 | Percent Institutions 74.62 |
Upturn AI SWOT
Pmv Pharmaceuticals Inc
Company Overview
History and Background
PMV Pharmaceuticals, Inc. is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies that selectively kill cancer cells by reactivating the p53 tumor suppressor protein. Founded in 2013, it focuses on cancers caused by p53 mutations, aiming to restore its function and induce apoptosis in cancer cells. The company has evolved from early-stage research to clinical-stage development.
Core Business Areas
- Oncology Therapeutics: Developing and commercializing small molecule therapeutics that target and reactivate the p53 tumor suppressor protein, with a focus on cancer cells with p53 mutations.
Leadership and Structure
Dr. David Alley serves as the Chief Executive Officer. The company has a typical corporate structure with executive leadership overseeing research, development, clinical operations, and commercial strategy.
Top Products and Market Share
Key Offerings
- PCM-012: PCM-012 is PMV Pharmaceuticals' lead drug candidate, a small molecule designed to selectively bind to and reactivate mutant p53 proteins in cancer cells. It is currently in Phase 1 clinical trials. Market share data is not yet applicable as it is still in clinical development. Key competitors in this field are companies developing p53-targeting therapies, including Aprea Therapeutics and Nutcracker Therapeutics.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, driven by unmet needs in cancer treatment. Precision oncology, targeting specific genetic mutations, is a growing area. The overall market is growing due to increased cancer diagnoses and advancements in treatment options.
Positioning
PMV Pharmaceuticals is positioned as a precision oncology company focused on p53 reactivation. Its competitive advantage lies in its specific approach of targeting mutant p53, which is a common mutation in many cancers.
Total Addressable Market (TAM)
The TAM for p53-targeted therapies is substantial, potentially reaching billions of dollars, given the prevalence of p53 mutations in cancer. PMV is positioning to capture a significant portion of this market if PCM-012 proves successful.
Upturn SWOT Analysis
Strengths
- Novel approach to targeting p53 mutations
- Strong scientific team
- Proprietary technology platform
Weaknesses
- Single lead product in early clinical development
- High cash burn rate
- Reliance on successful clinical trials
Opportunities
- Expanding pipeline with additional p53-targeting therapies
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to accelerated approval
Threats
- Clinical trial failures
- Competition from other p53-targeting therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- APRE
- NTRK
Competitive Landscape
PMV Pharmaceuticals has a competitive advantage in its specific approach to targeting mutant p53. However, it faces competition from other companies developing oncology therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is linked to successful clinical trial results and partnerships. Recent success can be observed by looking at the company stock's recent performance.
Future Projections: Future growth depends on clinical trial progress and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Initiatives include advancing PCM-012 through clinical trials and expanding the research pipeline.
Summary
PMV Pharmaceuticals is a clinical-stage precision oncology company focusing on reactivating the p53 tumor suppressor protein. It has a novel approach and proprietary technology but also faces risks due to its early-stage pipeline. Successful clinical trials are crucial for its future. Competition in the oncology space is strong. The company should watch out for clinical results and competition.
Similar Stocks
Sources and Disclaimers
Data Sources:
- PMV Pharmaceuticals website
- SEC filings
- Analyst reports
Disclaimers:
The data provided is for informational purposes only and does not constitute investment advice. Market share data is estimated. Financial results should be verified with official company documents.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pmv Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2020-09-25 | Co-Founder, CEO, President & Director Dr. David H. Mack Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 47 | Website https://www.pmvpharma.com |
Full time employees 47 | Website https://www.pmvpharma.com | ||
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.